Conclusion of a Non-Exclusive Discount Agreement Tender

• Country: Germany
• Summary: Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Interferon Beta-1B, Atc L03ab08 for the Period April 1St, 2024 - March 31St...
• DET Ref No: 97037643
• Deadline: 05 Feb 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: EUR 1.00
• Notice Type: Tender
• Document Ref. No.: 99345-2024
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Interferon Beta-1B, Atc L03ab08 for the Period April 1St, 2024 - March 31St, 2026
  Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory health insurance companies. With regard to the relevant legal regulations for the award of public contracts, seeet a regular process of active ingredient-related, formal award procedures takes place in accordance with the regulations of Part 4 of the GWB by DAK-Gesundheit. For medicinal products to be specified by the bidder in Annex 2 to the contract in relation to the above. Active ingredient, interferon beta-1b, ATC L03AB08, intends to DAK-Gesundheit is to conclude drug discount agreements with as many interested pharmaceutical companies as possible until new drug discount agreements come into force. A discount contract in the form of an approval model for the above-mentioned. The active ingredient comes into force for the first time on April 1, 2024 and ends on March 31, 2024026. Irrespective of this, it ends automatically when the exclusive contract comes into force.
  Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Interferon beta-1b, ATC L03AB08 for the period April 1st, 2024 - March 31st, 2026
  DAK-Gesundheit assumes that this procedureen does not fall within the scope of antitrust procurement law due to a lack of selection decision and therefore the non-discriminatory access of all pharmaceutical companies. Regardless, it ends automatically when the exclusive contract for interferon beta comes into force...
• Documents:

 Tender Notice